TD Cowen analyst Josh Jennings reiterated a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $135.00.
Josh Jennings has given his Buy rating due to a combination of factors that suggest a positive outlook for Abbott Laboratories. The company is expected to meet or exceed first-quarter expectations, which aligns with its 2025 guidance. This confidence is bolstered by the introduction of new products like TriClip in the US and Volt in Europe, which are anticipated to strengthen the core business despite potential macroeconomic challenges.
Furthermore, Abbott’s recent performance, including a robust organic core revenue growth of 10.1% and a notable 14.0% growth in its Medical Devices segment, supports the optimistic forecast. The company’s full-year guidance, which includes organic sales growth of 7.5-8.5% and an adjusted EPS of $5.05-$5.25, is expected to be achievable or even surpassable, given the current operating trends. Jennings’s analysis suggests that Abbott is well-positioned to continue its growth trajectory, making the stock a favorable investment opportunity.
In another report released on April 8, Oppenheimer also reiterated a Buy rating on the stock with a $134.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.